Desloratadine in Patients With Ulcerative Colitis
Phase 2 · Testing Desloratadine and mesalamine · 1 site · Tanta University
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
This study is testing Desloratadine (a drug) and mesalamine (a drug) as a possible treatment. Condition(s) listed: Ulcerative Colitis (UC) and Ulcerative Colitis.
Participants are assigned to groups by chance (randomized).
Some participants receive a placebo or sham for comparison.
It is open-label: participants know what they are receiving.
Phase 2 studies test whether a treatment shows signs of working, and keep checking safety, in a larger group of people with the condition.
Who can join
- Ages 18 to 65
- Any sex
Some of the main requirements, copied from the record:
- Both male and female sex.
- patients with age ranged from 18 to 65.
- patients with active mild and moderate ulcerative colitis according to American College of Gastroenterology (ACG) Clinical Guideline.
Plus 1 more requirement(s). There are also 9 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 44 participants are expected to take part.
- Start date: 2026-01-26.
- Main results expected around 2027-02 (estimate from the record).
- 1 study site listed (1 marked recruiting) in Egypt.
Main thing being measured
- Change in disease activity and severity (over a 3 month follow -up period)
In the researchers’ words
The purpose of this study is to investigate safety and therapeutic efficacy of antihistamine (desloratadine) on inflammation and disease activity when administered as adjuvant therapies with the traditional therapy 5-aminosalisylic acid (mesalamine) in patients with mild to moderate ulcerative colitis.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Recruiting |
|---|---|
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Ulcerative Colitis (UC); Ulcerative Colitis |
| Lead sponsor | Tanta University |
| Enrollment | 44 (estimated) |
| Start date | 2026-01-26 |
| Primary completion (est.) | 2027-02 |
| First posted | 2026-01-12 |
| Last updated | 2026-01-29 |
| Official title | Efficacy and Safety of Desloratadine as Adjuvant Therapy in Patients With Ulcerative Colitis |
| ClinicalTrials.gov ID | NCT07333716 |
Interventions
- Desloratadine (Drug)
mesalamine 1000 mg three times daily plus desloratadine 5 mg once daily for 3 months. - mesalamine (Drug)
mesalamine 1000 mg three times daily for 3 months
Full eligibility criteria (from the record)
Inclusion Criteria: * Both male and female sex. * patients with age ranged from 18 to 65. * patients with active mild and moderate ulcerative colitis according to American College of Gastroenterology (ACG) Clinical Guideline. * Patients treated with 5-aminosalisylic acid (mesalamine). Exclusion Criteria: * Patients with severe UC * Significant liver or kidney function abnormalities * Pregnant or lactating females * Treatment with systemic or rectal steroids * Treatment with immunosuppressant or biological therapies * Known allergy to desloratadine or any ingredient in the formulation * Patients with other inflammatory diseases * Patients with history of colon cancer * Patients with complete or partial colectomy
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| Menofia university Hospitals | Shibīn al Kawm, Menofia | Egypt | Recruiting |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.